Quantum Genomics (PAR: ALQGC)

Last close As at 12/07/2024

0.17

0.00 (2.35%)

Market capitalisation

EUR6m

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Latest Insights

View More

Healthcare | Flash note

Quantum Genomics — Firibastat misses endpoints in Phase III

Healthcare | Initiation

Quantum Genomics — A fresh take on cardiovascular medicine

Healthcare | Update

Quantum Genomics — Phase IIb QUORUM results

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.0 30.1 (91.0)
Relative 8.0 27.4 (92.2)
52 week high/low €4.0/€0.1

Financials

Edison Investment Research is terminating coverage on Quantum Genomics (ALQGC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 4.0 (13.1) (14.7) (72.0) N/A N/A
2021A 6.2 (14.9) (15.4) (58.0) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Investment Companies

Emerging markets – Worthy of consideration

thematic

Investment Companies

Dynam Capital at the 2024 Vietnam ESG Conference

thematic

TMT

MediaWatch – Glimpses of positivity

thematic

Consumer

ConsumerWatch – Give me a reason to love you

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free